Loading
institutionsInstitution
International Association for the Study of Lung Cancer
The only global society devoted to lung and thoracic cancers, whose World Conference on Lung Cancer and TNM staging project define the field.
Also called: IASLC
Overview
Founded in 1974, IASLC has more than 8,000 members in over 100 countries and publishes the Journal of Thoracic Oncology and JTO Clinical and Research Reports. Its Staging and Prognostic Factors Committee runs the international database behind the TNM classification for lung cancer, mesothelioma and thymic tumours (ninth edition 2024), and its World Conference on Lung Cancer is the annual venue for thoracic oncology trials, from EGFR and ALK inhibitors to neoadjuvant immunotherapy and ADCs. IASLC issues pathology and biomarker atlases (PD-L1, ALK, MET), the Lung Cancer Screening guidelines and the Grading System for lung adenocarcinoma, and its Tobacco Control Committee and Early Detection Committee drive global screening advocacy.
Location
Denver, CO, US
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#204 · 28 points (0 Newsweek + 0 NCI + 28 from 14 linked objects) · ranking
- World Conference on Lung Cancer
- TNM staging project for thoracic cancers
- Journal of Thoracic Oncology
- Biomarker and pathology atlases
- Screening and tobacco control advocacy
Caicun Zhou
Professor of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University; President, IASLC (2025-2027)
Lung cancerEGFR inhibitorsImmunotherapy
Principal investigator of HARMONi-2, the trial where ivonescimab beat pembrolizumab head-to-head, and of the first EGFR-TKI phase 3 in Chinese patients.
Karen Kelly
Chief Executive Officer
Thoracic oncologyLung cancer clinical trialsProfessional society leadership
Thoracic medical oncologist who serves as CEO of the International Association for the Study of Lung Cancer.
Yi-Long Wu
Professor; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital
Lung cancerEGFR-mutant NSCLCAdjuvant targeted therapy
Co-led ADAURA and IPASS, the trials that made EGFR-targeted pills standard before and after surgery.
Pasi A. Jänne
Director, Lowe Center for Thoracic Oncology; Director, Belfer Center for Applied Cancer Science
EGFR-mutant lung cancerTargeted therapy resistanceKRAS G12C
Co-discovered EGFR mutations in lung cancer and has led the drug development that followed, from osimertinib to KRAS G12C inhibitors.
Benjamin Solomon
Professor of Medical Oncology; Head, Lung Medical Oncology, Peter Mac
Lung cancerALK inhibitorsTargeted therapy
Principal investigator of CROWN, where lorlatinib produced the longest disease control ever recorded for a targeted lung cancer pill.
Fiona Blackhall
Professor of Thoracic Oncology, University of Manchester; Consultant, The Christie
Lung cancerSmall-cell lung cancerBiomarker-driven trials
Fiona Blackhall is a thoracic oncologist leading small-cell lung cancer trials and biomarker research at The Christie.
Similar pages
- InstitutionShanghai Pulmonary Hospital
Shares Caicun Zhou, CT (computed tomography), Small-cell lung cancer, Small-molecule kinase inhibitors.
- CompanyIntergroupe Francophone de Cancérologie Thoracique
Shares Oncogene addiction, Mesothelioma, Comprehensive genomic profiling, Small-cell lung cancer.
- CompanyChinese Thoracic Oncology Group
Shares Caicun Zhou, Yi-Long Wu, Non-small-cell lung cancer.
- TermPneumonitis
Shares CT (computed tomography), Mesothelioma, Small-cell lung cancer, Immune checkpoint inhibitors.
- InstitutionGuangdong Provincial People's Hospital
Shares Yi-Long Wu, Oncogene addiction, Comprehensive genomic profiling, Small-molecule kinase inhibitors.
- TrialStudy to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
- Key paperADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer
Shares Yi-Long Wu, Oncogene addiction, Resectable stage I to III non-small-cell lung cancer, Small-molecule kinase inhibitors.
- TrialStudy to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D,
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.